| Literature DB >> 35366033 |
Alexey Fomenko1, Stephanie Weibel2, Helia Moezi2, Kristina Menger2, Christine Schmucker3, Maria-Inti Metzendorf4, Edith Motschall5, Valeria Falcone1, Daniela Huzly1, Marcus Panning1, Gerta Rücker5, Hartmut Hengel1.
Abstract
The cornerstone of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection is reverse-transcription polymerase chain reaction (RT-PCR) of viral RNA. As a surrogate assay SARS-CoV-2 RNA detection does not necessarily imply infectivity. Only virus isolation in permissive cell culture systems can indicate infectivity. Here, we review the evidence on RT-PCR performance in detecting infectious SARS-CoV-2. We searched for any studies that used RT-PCR and cell culture to determine infectious SARS-CoV-2 in respiratory samples. We assessed (i) diagnostic accuracy of RT-PCR compared to cell culture as reference test, (ii) performed meta-analysis of positive predictive values (PPV) and (iii) determined the virus isolation probabilities depending on cycle threshold (Ct) or log10 genome copies/ml using logistic regression. We included 55 studies. There is substantial statistical and clinical heterogeneity. Seven studies were included for diagnostic accuracy. Sensitivity ranged from 90% to 99% and specificity from 29% to 92%. In meta-analysis, the PPVs varied across subgroups with different sampling times after symptom onset, with 1% (95% confidence interval [CI], 0%-7%) in sampling beyond 10 days and 27% (CI, 19%-36%) to 46% (CI, 33%-60%) in subgroups that also included earlier samples. Estimates of virus isolation probability varied between 6% (CI, 0%-100%) and 50% (CI, 0%-100%) at a Ct value of 30 and between 0% (CI, 0%-22%) and 63% (CI, 0%-100%) at 5 log10 genome copies/ml. Evidence on RT-PCR performance in detecting infectious SARS-CoV-2 in respiratory samples was limited. Major limitations were heterogeneity and poor reporting. RT-PCR and cell culture protocols need further standardisation.Entities:
Keywords: SARS-CoV-2; cell culture; infectivity; real-time polymerase chain reaction; systematic review
Mesh:
Substances:
Year: 2022 PMID: 35366033 PMCID: PMC9111068 DOI: 10.1002/rmv.2342
Source DB: PubMed Journal: Rev Med Virol ISSN: 1052-9276 Impact factor: 11.043
FIGURE 1PRISMA flow diagram demonstrating the literature selection process
Summary of characteristics of included studies
| All studies ( | ||
|---|---|---|
|
| % | |
| Study design | ||
| Case series | 31 | 56.4 |
| Diagnostic test accuracy study | 14 | 25.5 |
| Cross‐sectional | 8 | 14.5 |
| Cohort | 2 | 3.6 |
| Continent | ||
| Europe | 26 | 47.3 |
| North America | 14 | 25.5 |
| Asia | 13 | 23.6 |
| South America | 1 | 1.8 |
| Australia | 1 | 1.8 |
| Period of the conduct of included studies | 01/20–01/21 | |
| Age groups | ||
| Mixed | 17 | 30.9 |
| Adults | 16 | 29.1 |
| Children | 1 | 1.8 |
| NR | 18 | 32.7 |
| Symptom status | ||
| Mixed (symptomatic‐asymptomatic‐postsymptomatic) | 22 | 40 |
| Symptomatic | 11 | 20 |
| Postsymptomatic | 3 | 5.5 |
| Asymptomatic | 1 | 1.8 |
| NR | 18 | 32.7 |
| Sample size | ||
| Range | 4‐3790 | |
| Median (IQR) | 73.5 (35–121.2) | |
| Sampling time post symptom onset | ||
| Early mixed (presymptomatic, 0‐10 d, >10 d) | 3 | 5.5 |
| Within 10 d | 6 | 10.9 |
| Late mixed (0‐10 d, >10 d) | 24 | 43.6 |
| Beyond 10d | 9 | 16.4 |
| NR | 13 | 23.6 |
| Sample types | ||
| NPS | 16 | 29.1 |
| Other mixed | 16 | 29.1 |
| Mixed NPS, OPS | 10 | 18 |
| Nasal | 3 | 5.5 |
| Mixed NPS, OPS, Sputum | 3 | 5.5 |
| Saliva | 2 | 3.6 |
| OPS | 2 | 3.6 |
| Sputum | 1 | 1.8 |
| NR | 2 | 3.6 |
| Cell line used for cell culture | ||
| Vero E6 cells | 24 | 43.6 |
| Vero CCL‐81 cells | 12 | 21.8 |
| Vero E6‐TMPRSS2 cells | 5 | 9 |
| Vero cells | 4 | 7.3 |
| Vero C1008 cells | 2 | 3.6 |
| Vero clone 118 cells | 2 | 3.6 |
| Caco‐2 cells | 2 | 3.6 |
| Vero B4 cells | 1 | 1.8 |
| Mixed Vero E6 and ML‐2 cells | 1 | 1.8 |
| Vero‐TMPRSS2 cells | 1 | 1.8 |
| NR | 1 | 1.8 |
| Confirmation method of the cytopathic effect | ||
| RT‐PCR | 31 | 56.4 |
| Transmission electron microscope | 1 | 1.8 |
| (scanning) EM and RT‐PCR | 2 | 3.6 |
| IF (Anti‐N‐Ab) | 4 | 7.3 |
| IF (Anti‐S‐Ab) | 1 | 1.8 |
| Plaque assay and IF (Anti‐N‐Ab | 1 | 1.8 |
| RT‐PCR or IF (Anti‐S‐Ab) | 1 | 1.8 |
| RT‐PCR or IF (Anti‐N‐Ab) | 1 | 1.8 |
| RT‐PCR and IF (Anti‐N‐Ab) | 1 | 1.8 |
| RT‐PCR and plaque assay | 1 | 1.8 |
| Plaque assay | 1 | 1.8 |
| Reinfection in new Vero monolayers | 1 | 1.8 |
| NR | 9 | 16.4 |
| Passaging | ||
| Performed | 13 | 23.6 |
| Not performed | 2 | 3.6 |
| NR | 40 | 72.3 |
| Cell culture positive definition | ||
| Reported | 13 | 23.6 |
| Not reported | 42 | 74.4 |
| RT‐PCR assay | ||
| In‐house | 30 | 54.5 |
| Commercial | 14 | 25.4 |
| Mixed | 9 | 16.4 |
| NR | 2 | 3.6 |
| Target genes reported for viral load quantification | ||
| N (1‐3, 1, 2) | 21 | 38.1 |
| E | 12 | 21.8 |
| ORF1ab | 2 | 3.6 |
| RdRP | 2 | 3.6 |
| S | 2 | 3.6 |
| E, RdRP, N | 2 | 3.6 |
| ORF1ab | 2 | 3.6 |
| E pp1ab | 1 | 1.8 |
| S, Nsp2 | 1 | 1.8 |
| N, S, ORF1ab | 1 | 1.8 |
| ORF1ab, N | 1 | 1.8 |
| E, Nsp12, N | 1 | 1.8 |
| E, S | 1 | 1.8 |
| ORF1ab, N, E, RdRP | 1 | 1.8 |
| E, N | 1 | 1.8 |
| NR | 4 | 7.3 |
Abbreviations: anti‐N‐Ab, anti‐nucleoprotein antibody; Anti‐S‐Ab, anti‐spike antibody; d, days; E, envelope protein gene; IF, immunofluorescence; N, nucleocapsid protein gene; NR, not reported; NPS, nasopharyngeal swab; Nsp2/12, nonstructural proteins 2/12 gene; OPS, oropharyngeal swab; ORF1ab, open reading frame 1ab gene; pp1ab, polyprotein 1ab; RdRP, RNA‐dependant RNA‐Polymerase gene; RT‐PCR, reverse transcription polymerase chain reaction; S, spike protein gene; SD, standard deviation; TMPRSS2, transmembrane protease; serine 2‐expressing Vero cells.
FIGURE 2Forest plot of sensitivity and specificity estimates of reverse‐transcription polymerase chain reaction (RT‐PCR) for detection of infectious specimen compared to cell culture as reference standard. The squares and horizontal lines represent the point estimate and 95% confidence interval (CI) for each included study
FIGURE 3Forest plot shows random effect meta‐analysis of positive predictive values|positive predictive value (PPV) for virus isolation in total reverse‐transcription polymerase chain reaction (RT‐PCR) positive respiratory samples, subgrouped by sampling time post symptom onset. 5 Subgroups based on sampling time: (1). Early mixed sampling (presymptomatic, 0–10 days, >10 days), (2). Within 10 days, (3). Late mixed (0–10 days, >10 days), (4). Beyond 10 days, (5). Sampling time not reported. TP – true positive, FP – false positive, Total = TP + FP
FIGURE 4Overview of virus isolation probability curves assessed by logistic regression. Virus culture outcomes are plotted against Ct values (N = 9) (a) or log10 genome copies/ml (n = 5) (b) in a common coordinate to allow visual comparability of the curves. Estimation of virus isolation probability is represented by lines for each study. Colouration of the lines represents specific study, dashed or dotted lines have been used if studies provided Ct values for several target genes. For clearity reasons the 95% confidence intervals of the estimates are depicted for each study in supplementary material (S13‐32). (a) Overview of virus isolation probability versus cycle threshold. The dotted vertical line represents Ct of 30 and corresponding virus isolation probability estimates are depicted in the legend. (b) Overview of virus isolation probability versus log10 genome copies/ml. The dotted vertical line represents 5 log10 genome copies/ml and corresponding virus isolation probability estimates are depicted in the legend